The lung is one of the most commonly encountered sites of Scedosporium
infection. Due to its intrinsic resistance to all current antifungal
agents, treatment of Scedosporium infections still remains a great
challenge. Voriconazole has been recommended to the first-line systemic
treatment of Scedosporium infections, but the duration is not well
recommended, especially for immunocompetent patients. This case series
presented our experience on diagnostic, manifestation, and treatment
strategies of Scedosporium pneumonia. The case records of
non-Transplanted non-HIV adults with Scedosporium pneumonia hospitalized
in our Hospital from January 2020 to February 2022 were retrospectively
analyzed, and their case characteristics, antifungal therapy drug
selection and treatment course were summarized: All 3 patients had
underlying lung disease, 2 female patients had a history of
bronchiectasis, and 1 male patient had a history of emphysema. Both
female patients had a mixed infection with Scedosporium and
nontuberculous mycobacteria. In one female patients, Scedosporium was no
longer detected after 2 months of treatment with voriconazole, and the
clinical symptoms were improved than before, with no significant change
in imaging. In one female patient, although Scedosporium was still
isolated from sputum after 12 months with voriconazole treatment, the
symptoms were improved than before, and antifungal therapy was
discontinued after no significant improvement 1 and a half months after
switching to Posaconazole. In one male patient, Scedosporium was no
longer detected after 3 months treatment with voriconazole, and the
clinical symptoms and imaging were significantly improved. Three
patients had voriconazole concentrations between 1.1-2.8 μg/mL during
treatment.